These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 25582328)

  • 1. p21-activated kinase 4: a druggable target in the elusive oncogenic KRAS pathway?
    Azmi AS; Mohammad RM
    Future Med Chem; 2015; 7(1):5-7. PubMed ID: 25582328
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulation of KRAS-PAK4 axis by microRNAs in cancer.
    Choudhry ZS; Tripathi V; Sutton M; Bao B; Mohammad RM; Azmi AS
    Curr Pharm Des; 2014; 20(33):5275-8. PubMed ID: 24479809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of p21-activated kinases in pancreatic cancer.
    Yeo D; He H; Baldwin GS; Nikfarjam M
    Pancreas; 2015 Apr; 44(3):363-9. PubMed ID: 25760284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of p21-activated kinases (PAKs).
    Rudolph J; Crawford JJ; Hoeflich KP; Wang W
    J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of allosteric inhibitors of p21-activated kinase.
    Viaud J; Peterson JR
    Methods Mol Biol; 2012; 928():67-79. PubMed ID: 22956134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation.
    Wang K; Baldwin GS; Nikfarjam M; He H
    World J Gastroenterol; 2018 Sep; 24(33):3709-3723. PubMed ID: 30197477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAK4 interacts with p85 alpha: implications for pancreatic cancer cell migration.
    King H; Thillai K; Whale A; Arumugam P; Eldaly H; Kocher HM; Wells CM
    Sci Rep; 2017 Feb; 7():42575. PubMed ID: 28205613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain.
    Kim DJ; Choi CK; Lee CS; Park MH; Tian X; Kim ND; Lee KI; Choi JK; Ahn JH; Shin EY; Shin I; Kim EG
    Exp Mol Med; 2016 Apr; 48(4):e229. PubMed ID: 27126178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAK'n it in: identification of a selective PAK inhibitor.
    Bokoch GM
    Chem Biol; 2008 Apr; 15(4):305-6. PubMed ID: 18420134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
    Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
    Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of 1-phenanthryl-tetrahydroisoquinoline derivatives as novel p21-activated kinase 4 (PAK4) inhibitors.
    Song S; Li X; Guo J; Hao C; Feng Y; Guo B; Liu T; Zhang Q; Zhang Z; Li R; Wang J; Lin B; Li F; Zhao D; Cheng M
    Org Biomol Chem; 2015 Mar; 13(12):3803-18. PubMed ID: 25705811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p21-activated kinase inhibitors.
    Rudolph J; Crawford JJ; Hoeflich KP; Chernoff J
    Enzymes; 2013; 34 Pt. B():157-80. PubMed ID: 25034104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification.
    Chen S; Auletta T; Dovirak O; Hutter C; Kuntz K; El-ftesi S; Kendall J; Han H; Von Hoff DD; Ashfaq R; Maitra A; Iacobuzio-Donahue CA; Hruban RH; Lucito R
    Cancer Biol Ther; 2008 Nov; 7(11):1793-802. PubMed ID: 18836286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategy and validation of a structure-based method for the discovery of selective inhibitors of PAK isoforms and the evaluation of their anti-cancer activity.
    Song PL; Wang G; Su Y; Wang HX; Wang J; Li F; Cheng MS
    Bioorg Chem; 2019 Oct; 91():103168. PubMed ID: 31400553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.
    Shao YG; Ning K; Li F
    World J Gastroenterol; 2016 Jan; 22(3):1224-35. PubMed ID: 26811660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Potential of Targeting PAK Signaling.
    Senapedis W; Crochiere M; Baloglu E; Landesman Y
    Anticancer Agents Med Chem; 2016; 16(1):75-88. PubMed ID: 26081410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer.
    Chuang HC; Huang PH; Kulp SK; Chen CS
    Pharmacol Res; 2017 Mar; 117():370-376. PubMed ID: 28077300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.
    Tabusa H; Brooks T; Massey AJ
    Mol Cancer Res; 2013 Feb; 11(2):109-21. PubMed ID: 23233484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently.
    Viaud J; Peterson JR
    Mol Cancer Ther; 2009 Sep; 8(9):2559-65. PubMed ID: 19723886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p21-Activated kinase inhibitors: a patent review.
    Crawford JJ; Hoeflich KP; Rudolph J
    Expert Opin Ther Pat; 2012 Mar; 22(3):293-310. PubMed ID: 22404134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.